Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005859
Status:
COMPLETED
Last Update Posted:
2018-06-26
First Post:
2000-06-02
Brief Title:
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Overview
Official Title:
Phase III Trial of R115777 in Patients With Recurrent Malignant Glioma
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
PURPOSE Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or progressive malignant glioma
PURPOSE Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or progressive malignant glioma
Detailed Description:
OBJECTIVES
Determine the maximum tolerated dose of tipifarnib in patients with recurrent or progressive malignant glioma receiving enzyme-inducing antiepileptic drugs Stratum II in the phase I portion of this study closed to accrual effective 07162001 Phase I completed effective 1022001 Phase II open only to patients requiring resection and who provide surgical tissue samples effective 3132003
Define the safety and pharmacokinetic profile of this drug in this patient population
Assess for evidence of antitumor activity of this drug in these patients
Assess for evidence of inhibition of farnesyl protein transferase FTase on peripheral blood monocytes as a surrogate endpoint of effective biologic activity of this drug in these patients
Determine the efficacy of this drug as measured by 6-month progression-free survival and objective tumor response in these patients
Evaluate further the safety profile of this drug in these patients
Correlate treatment response with inhibition of FTase in peripheral blood monocytes in patients treated with this drug
OUTLINE This is a dose-escalation multicenter study Patients are stratified according to their pretreatment medications not receiving enzyme-inducing antiepileptic drugs EIAEDs vs receiving EIAEDs with or without steroids
Patients receive oral tipifarnib twice daily on days 1-21 Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression
Phase I completed 1022001 Cohorts of 3-6 patients from stratum II receive escalating doses of tipifarnib until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity Stratum II in the phase I portion of this study closed to accrual effective 07162001
Phase II open only to patients requiring resection and who provide surgical tissue samples effective 3132003 Once the MTD is determined additional patients with glioblastoma multiforme from stratum II are accrued to receive treatment with tipifarnib at the recommended phase II dose
Patients are followed every 2 months for 1 year every 3 months for 1 year every 4 months for 1 year and then every 6 months until progression Patients are then followed every 4 months thereafter
PROJECTED ACCRUAL Approximately 30 patients 15 per stratum will be accrued for the phase I portion of this study within 10 months Stratum II in the phase I portion of this study closed to accrual effective 07162001 Phase I completed effective 1022001 A total of 24 patients with glioblastoma multiforme from stratum II will be accrued for the phase II portion of this study Phase II open only to patients requiring resection and who provide surgical tissue samples effective 3132003
Determine the maximum tolerated dose of tipifarnib in patients with recurrent or progressive malignant glioma receiving enzyme-inducing antiepileptic drugs Stratum II in the phase I portion of this study closed to accrual effective 07162001 Phase I completed effective 1022001 Phase II open only to patients requiring resection and who provide surgical tissue samples effective 3132003
Define the safety and pharmacokinetic profile of this drug in this patient population
Assess for evidence of antitumor activity of this drug in these patients
Assess for evidence of inhibition of farnesyl protein transferase FTase on peripheral blood monocytes as a surrogate endpoint of effective biologic activity of this drug in these patients
Determine the efficacy of this drug as measured by 6-month progression-free survival and objective tumor response in these patients
Evaluate further the safety profile of this drug in these patients
Correlate treatment response with inhibition of FTase in peripheral blood monocytes in patients treated with this drug
OUTLINE This is a dose-escalation multicenter study Patients are stratified according to their pretreatment medications not receiving enzyme-inducing antiepileptic drugs EIAEDs vs receiving EIAEDs with or without steroids
Patients receive oral tipifarnib twice daily on days 1-21 Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression
Phase I completed 1022001 Cohorts of 3-6 patients from stratum II receive escalating doses of tipifarnib until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity Stratum II in the phase I portion of this study closed to accrual effective 07162001
Phase II open only to patients requiring resection and who provide surgical tissue samples effective 3132003 Once the MTD is determined additional patients with glioblastoma multiforme from stratum II are accrued to receive treatment with tipifarnib at the recommended phase II dose
Patients are followed every 2 months for 1 year every 3 months for 1 year every 4 months for 1 year and then every 6 months until progression Patients are then followed every 4 months thereafter
PROJECTED ACCRUAL Approximately 30 patients 15 per stratum will be accrued for the phase I portion of this study within 10 months Stratum II in the phase I portion of this study closed to accrual effective 07162001 Phase I completed effective 1022001 A total of 24 patients with glioblastoma multiforme from stratum II will be accrued for the phase II portion of this study Phase II open only to patients requiring resection and who provide surgical tissue samples effective 3132003
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067888 | REGISTRY | None | None |
| U01CA062455 | NIH | PDQ Physician Data Query | httpsreporternihgovquickSearchU01CA062455 |